NZ603790A - Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof - Google Patents
Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereofInfo
- Publication number
- NZ603790A NZ603790A NZ603790A NZ60379009A NZ603790A NZ 603790 A NZ603790 A NZ 603790A NZ 603790 A NZ603790 A NZ 603790A NZ 60379009 A NZ60379009 A NZ 60379009A NZ 603790 A NZ603790 A NZ 603790A
- Authority
- NZ
- New Zealand
- Prior art keywords
- alphavirus
- ires
- attenuated
- entry site
- ribosomal entry
- Prior art date
Links
- 241000710929 Alphavirus Species 0.000 title abstract 9
- 230000002238 attenuated effect Effects 0.000 title abstract 6
- 241000255925 Diptera Species 0.000 title 1
- 230000003362 replicative effect Effects 0.000 title 1
- 108091027544 Subgenomic mRNA Proteins 0.000 abstract 3
- 210000003705 ribosome Anatomy 0.000 abstract 3
- 108091026890 Coding region Proteins 0.000 abstract 2
- 241000710188 Encephalomyocarditis virus Species 0.000 abstract 2
- 101710121417 Envelope glycoprotein Proteins 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 2
- 210000000234 capsid Anatomy 0.000 abstract 2
- 210000004962 mammalian cell Anatomy 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 108020005345 3' Untranslated Regions Proteins 0.000 abstract 1
- 101710159910 Movement protein Proteins 0.000 abstract 1
- 101710144117 Non-structural protein 4 Proteins 0.000 abstract 1
- 101800001758 RNA-directed RNA polymerase nsP4 Proteins 0.000 abstract 1
- 230000000977 initiatory effect Effects 0.000 abstract 1
- 230000037431 insertion Effects 0.000 abstract 1
- 238000003780 insertion Methods 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 238000011144 upstream manufacturing Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36161—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6222908P | 2008-01-24 | 2008-01-24 | |
| NZ587502A NZ587502A (en) | 2008-01-24 | 2009-01-23 | Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ603790A true NZ603790A (en) | 2014-08-29 |
Family
ID=41217313
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ603790A NZ603790A (en) | 2008-01-24 | 2009-01-23 | Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof |
| NZ587502A NZ587502A (en) | 2008-01-24 | 2009-01-23 | Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ587502A NZ587502A (en) | 2008-01-24 | 2009-01-23 | Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US8426188B2 (https=) |
| EP (2) | EP2250269B1 (https=) |
| JP (1) | JP5758632B2 (https=) |
| KR (2) | KR101668849B1 (https=) |
| CN (1) | CN102083986B (https=) |
| AU (1) | AU2009238667A1 (https=) |
| CA (2) | CA2910235C (https=) |
| CO (1) | CO6290702A2 (https=) |
| IL (2) | IL207167A (https=) |
| MX (3) | MX367792B (https=) |
| MY (1) | MY178870A (https=) |
| NZ (2) | NZ603790A (https=) |
| SG (2) | SG187513A1 (https=) |
| WO (1) | WO2009131604A2 (https=) |
| ZA (1) | ZA201005943B (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2947149T3 (en) * | 2007-06-21 | 2018-06-06 | Alphavax Inc | ALPHAVIRUS REPLICATION PARTICLES FOR USE IN VACCINATION |
| SG187513A1 (en) | 2008-01-24 | 2013-02-28 | Univ Texas | Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof |
| US8961995B2 (en) | 2012-09-20 | 2015-02-24 | Uab Research Foundation | Methods and compositions for alphavirus replicons |
| EP2900685B1 (en) | 2012-09-27 | 2017-10-25 | Research Development Foundation | Attenuated chikungunya virus |
| JP6426695B2 (ja) | 2013-03-14 | 2018-11-21 | タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. | 弱毒生アルファウイルス製剤のための組成物および方法 |
| US20190106682A1 (en) * | 2016-03-31 | 2019-04-11 | Takeda Vaccines, Inc. | Live, Attenuated Alphavirus Constructs and Methods and Uses Thereof |
| CN109476708B (zh) * | 2016-05-27 | 2023-12-22 | 格里菲斯大学 | 针对致关节炎甲病毒的疫苗 |
| MX2019013259A (es) | 2017-05-08 | 2020-01-13 | Gritstone Oncology Inc | Vectores de neoantigeno de alfavirus. |
| SG11202005792RA (en) | 2017-12-20 | 2020-07-29 | Vlp Therapeutics Llc | Alphavirus replicon particle |
| CA3111440A1 (en) * | 2018-08-03 | 2020-02-06 | Uab Research Foundation | Methods and compositions for alphavirus vaccine |
| CN109536464B (zh) * | 2018-12-10 | 2022-06-10 | 中国科学院武汉病毒研究所 | 一种缺失衣壳蛋白基因的基孔肯雅病毒感染性克隆及构建方法和在制备减毒疫苗中的应用 |
| MX2021014525A (es) | 2019-05-30 | 2022-03-17 | Gritstone Bio Inc | Adenovirus modificados. |
| WO2021138447A1 (en) | 2019-12-31 | 2021-07-08 | Elixirgen Therapeutics, Inc. | Temperature-based transient delivery of nucleic acids and proteins to cells and tissues |
| KR20230046313A (ko) | 2020-08-06 | 2023-04-05 | 그릿스톤 바이오, 인코포레이티드 | 다중에피토프 백신 카세트 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6451592B1 (en) * | 1996-04-05 | 2002-09-17 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
| CA2327189A1 (en) * | 2000-12-21 | 2002-06-21 | The Minister Of National Defence | Novel dna-based vaccine against the encephalitis alphaviruses |
| CN1791678A (zh) * | 2003-03-20 | 2006-06-21 | 阿尔法瓦克斯公司 | 改进的甲病毒复制子和辅助构建体 |
| CA2533614C (en) | 2004-07-30 | 2011-05-03 | Research In Motion Limited | Method and system for coordinating device setting between a communications client and its host device |
| US7332322B2 (en) | 2004-09-14 | 2008-02-19 | Ilya Frolov | Venezuelan equine encephalitis virus replicons with adaptive mutations in the genome and uses thereof |
| CA2579507C (en) | 2006-03-15 | 2017-06-13 | Institut Pasteur | Novel isolated and purified strains of chikungunya virus and polynucleotides and polypeptides sequences, diagnostic and immunogenical uses thereof |
| SG187513A1 (en) * | 2008-01-24 | 2013-02-28 | Univ Texas | Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof |
-
2009
- 2009-01-23 SG SG2013005624A patent/SG187513A1/en unknown
- 2009-01-23 NZ NZ603790A patent/NZ603790A/en not_active IP Right Cessation
- 2009-01-23 MX MX2014010258A patent/MX367792B/es unknown
- 2009-01-23 CA CA2910235A patent/CA2910235C/en not_active Expired - Fee Related
- 2009-01-23 EP EP09735287.6A patent/EP2250269B1/en not_active Not-in-force
- 2009-01-23 WO PCT/US2009/000458 patent/WO2009131604A2/en not_active Ceased
- 2009-01-23 MY MYPI2010003463A patent/MY178870A/en unknown
- 2009-01-23 EP EP16000617.7A patent/EP3085787B1/en not_active Not-in-force
- 2009-01-23 SG SG10201606111XA patent/SG10201606111XA/en unknown
- 2009-01-23 NZ NZ587502A patent/NZ587502A/xx not_active IP Right Cessation
- 2009-01-23 MX MX2010007989A patent/MX2010007989A/es active IP Right Grant
- 2009-01-23 AU AU2009238667A patent/AU2009238667A1/en not_active Abandoned
- 2009-01-23 MX MX2019010530A patent/MX378503B/es unknown
- 2009-01-23 CN CN200980110510.1A patent/CN102083986B/zh not_active Expired - Fee Related
- 2009-01-23 KR KR1020107018777A patent/KR101668849B1/ko not_active Expired - Fee Related
- 2009-01-23 KR KR1020167029024A patent/KR101913790B1/ko not_active Expired - Fee Related
- 2009-01-23 CA CA2713165A patent/CA2713165C/en not_active Expired - Fee Related
- 2009-01-23 JP JP2010544350A patent/JP5758632B2/ja not_active Expired - Fee Related
-
2010
- 2010-07-22 IL IL207167A patent/IL207167A/en active IP Right Grant
- 2010-07-23 US US12/804,535 patent/US8426188B2/en active Active
- 2010-08-20 CO CO10102866A patent/CO6290702A2/es active IP Right Grant
- 2010-08-20 ZA ZA2010/05943A patent/ZA201005943B/en unknown
-
2013
- 2013-04-03 US US13/855,960 patent/US9580690B2/en active Active
-
2014
- 2014-04-09 IL IL232032A patent/IL232032A0/en unknown
-
2017
- 2017-02-27 US US15/443,364 patent/US10533186B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ603790A (en) | Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof | |
| Varnavski et al. | Stable high-level expression of heterologous genes in vitro and in vivo by noncytopathic DNA-based Kunjin virus replicon vectors | |
| Qu et al. | Circular RNA vaccines against SARS-CoV-2 and emerging variants | |
| Publicover et al. | A single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector | |
| Sasaki et al. | Translation initiation at the CUU codon is mediated by the internal ribosome entry site of an insect picorna-like virus in vitro | |
| Bell et al. | Control of alphavirus-based gene expression using engineered riboswitches | |
| EP0753053B1 (en) | ALPHAVIRUS cDNA VECTORS | |
| Perri et al. | An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector | |
| JP2015527296A5 (https=) | ||
| Anraku et al. | Kunjin virus replicon vaccine vectors induce protective CD8+ T-cell immunity | |
| Waring et al. | MicroRNA-based attenuation of influenza virus across susceptible hosts | |
| CN118086288B (zh) | 多顺反子的自放大rna及制备方法 | |
| JP2011523347A5 (https=) | ||
| Thomas et al. | Sindbis virus vectors designed to express a foreign protein as a cleavable component of the viral structural polyprotein | |
| JP2019509750A5 (https=) | ||
| Dominguez et al. | Alphavirus-based replicons demonstrate different interactions with host cells and can be optimized to increase protein expression | |
| Rodriguez Pulido et al. | Attenuated foot-and-mouth disease virus RNA carrying a deletion in the 3′ noncoding region can elicit immunity in swine | |
| CN102250950A (zh) | 一种基于dna水平的乙型脑炎病毒复制子载体系统及其构建方法和应用 | |
| Kim et al. | Design of chimeric alphaviruses with a programmed, attenuated, cell type-restricted phenotype | |
| Bhomia et al. | Artificial microRNAs can effectively inhibit replication of Venezuelan equine encephalitis virus | |
| Casmil et al. | Alphaviral backbone of self-amplifying RNA enhances protein expression and immunogenicity against SARS-CoV-2 antigen | |
| Schmid et al. | A versatile RNA vector for delivery of coding and noncoding RNAs | |
| Lundstrom | Self-replicating RNA viral vectors in vaccine development and gene therapy | |
| Wu et al. | Broad-spectrum antiviral activity of RNA interference against four genotypes of Japanese encephalitis virus based on single microRNA polycistrons | |
| PH12018502197A1 (en) | Improved method for producing virus like particles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 23 JAN 2016 BY CPA GLOBAL Effective date: 20150314 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 JAN 2017 BY CPA GLOBAL Effective date: 20151224 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 JAN 2018 BY CPA GLOBAL Effective date: 20170113 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 JAN 2019 BY CPA GLOBAL Effective date: 20180123 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 JAN 2020 BY COMPUTER PACKAGES INC Effective date: 20190101 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 JAN 2021 BY COMPUTER PACKAGES INC Effective date: 20191231 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 JAN 2022 BY COMPUTER PACKAGES INC Effective date: 20201231 |
|
| LAPS | Patent lapsed |